Thomson Horstmann & Bryant Inc. Acquires Shares of 229,944 Anika Therapeutics Inc. (NASDAQ:ANIK)

Thomson Horstmann & Bryant Inc. acquired a new stake in Anika Therapeutics Inc. (NASDAQ:ANIK) during the second quarter, according to its most recent filing with the SEC. The firm acquired 229,944 shares of the biotechnology company’s stock, valued at approximately $11,345,000. Anika Therapeutics makes up about 1.5% of Thomson Horstmann & Bryant Inc.’s portfolio, making the stock its 17th largest position. Thomson Horstmann & Bryant Inc. owned 1.57% of Anika Therapeutics at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the stock. AMI Asset Management Corp boosted its stake in shares of Anika Therapeutics by 23.0% in the second quarter. AMI Asset Management Corp now owns 309,059 shares of the biotechnology company’s stock worth $15,249,000 after buying an additional 57,797 shares in the last quarter. Eqis Capital Management Inc. boosted its stake in shares of Anika Therapeutics by 0.6% in the second quarter. Eqis Capital Management Inc. now owns 36,459 shares of the biotechnology company’s stock worth $1,799,000 after buying an additional 229 shares in the last quarter. State of Alaska Department of Revenue boosted its stake in shares of Anika Therapeutics by 79.5% in the second quarter. State of Alaska Department of Revenue now owns 2,872 shares of the biotechnology company’s stock worth $141,000 after buying an additional 1,272 shares in the last quarter. Fisher Asset Management LLC boosted its stake in shares of Anika Therapeutics by 15.3% in the second quarter. Fisher Asset Management LLC now owns 80,904 shares of the biotechnology company’s stock worth $3,992,000 after buying an additional 10,751 shares in the last quarter. Finally, Bank of Montreal Can raised its position in Anika Therapeutics by 12.4% in the second quarter. Bank of Montreal Can now owns 21,190 shares of the biotechnology company’s stock valued at $1,046,000 after buying an additional 2,341 shares during the last quarter. Institutional investors and hedge funds own 82.25% of the company’s stock.

Anika Therapeutics Inc. (ANIK) traded up 0.27% during midday trading on Friday, hitting $52.82. 489,516 shares of the company traded hands. The stock has a 50 day moving average of $49.79 and a 200 day moving average of $47.14. Anika Therapeutics Inc. has a 12-month low of $41.38 and a 12-month high of $53.99. The stock has a market cap of $774.24 million, a P/E ratio of 23.47 and a beta of 1.69.

Anika Therapeutics (NASDAQ:ANIK) last announced its earnings results on Wednesday, July 26th. The biotechnology company reported $0.76 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.44 by $0.32. The company had revenue of $33.50 million for the quarter, compared to analyst estimates of $27.20 million. Anika Therapeutics had a return on equity of 14.88% and a net margin of 30.44%. The firm’s quarterly revenue was up 25.9% compared to the same quarter last year. During the same quarter last year, the company earned $0.57 earnings per share. Equities research analysts predict that Anika Therapeutics Inc. will post $2.20 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Thomson Horstmann & Bryant Inc. Acquires Shares of 229,944 Anika Therapeutics Inc. (NASDAQ:ANIK)” was first posted by BNB Daily and is the sole property of of BNB Daily. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.baseball-news-blog.com/2017/08/19/thomson-horstmann-bryant-inc-purchases-new-stake-in-anika-therapeutics-inc-nasdaqanik-updated-updated-updated.html.

Several research analysts have recently commented on ANIK shares. Zacks Investment Research downgraded shares of Anika Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, May 8th. BidaskClub upgraded shares of Anika Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, August 8th.

In other Anika Therapeutics news, CEO Charles H. Sherwood sold 63,799 shares of the firm’s stock in a transaction on Thursday, July 27th. The stock was sold at an average price of $50.79, for a total value of $3,240,351.21. Following the sale, the chief executive officer now owns 174,705 shares of the company’s stock, valued at approximately $8,873,266.95. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Jeffery S. Thompson sold 10,725 shares of the firm’s stock in a transaction on Monday, May 22nd. The shares were sold at an average price of $47.39, for a total value of $508,257.75. Following the completion of the sale, the director now directly owns 15,845 shares in the company, valued at approximately $750,894.55. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 88,725 shares of company stock worth $4,459,085. Corporate insiders own 6.57% of the company’s stock.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.

Institutional Ownership by Quarter for Anika Therapeutics (NASDAQ:ANIK)

Receive News & Ratings for Anika Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply